Myeloproliferative Neoplasms (MPNs) [Excluding CML]

- **Myelofibrosis (PMF)**
  - Primary Myelofibrosis (PMF)
  - FGFR1 Rearrangement

- **Hypereosinophilic Syndrome (HES)**
  - Hypereosinophilic Syndrome (HES)

- **HEMMPD0038**
  - Phase II Ruxolitinib in Idiopathic Hypereosinophilic Syndrome & Primary Eosinophilic Disorders
    - PI: Gotlib Incyte Corporation

- **HEMMPD0041**
  - Phase II Venetoclax in Combo w/ Decitabine in Accelerated & Blast-Phase Myeloproliferative Neoplasms
    - PI: Shomali Pending

- **HEMMPD0028**
  - Phase II INCB054828 in Myeloid/ Lymphoid Neoplasms With FGFR1 Rearrangement
    - PI: Gotlib Incyte Corporation

- **HEMMPD0035**
  - Phase II Ruxolitinib in Idiopathic Hypereosinophilic Syndrome - Dependent Polycythemia Vera
    - PI: Gotlib Stanford

- **HEMMPD0040**
  - Phase IIa/IIb KRT-232 Compared to Ruxolitinib in Phlebotomy-Dependent Polycythemia Vera
    - PI: Gotlib Protagonist Therapeutics, Inc.

- **HEMMPD0036**
  - Phase 2a/b of KRT-232 in PMF, Post-PV-MF, or Post-ET-MF
    - PI: Gotlib Sponsor: Kartos Therapeutics

**KEY**
- **Pending**
- **Open for Enrollment**
- **Link**
- **Trial Posting**
- **Extension Study**
- **Immunotherapy**
- **Optional Path**
- **Enrollment on Hold**